Non-Current Liabilities
Other Non-Current Liabilities
Royalty Pharma Other Non-Current Liabilities decreased by 2.5% to $117.79M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 558.0%, from $17.90M to $117.79M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryRisk
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
Metric ID:
other_non_current_liabilitiesHistorical Data
17 periods
| Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $43.70M | $9.90M | $2.50M | $12.30M | $8.50M | $11.30M | $900.00K | $3.22M | $27.04M | $5.58M | $12.08M | $17.90M | $143.33M | $126.94M | $120.84M | $117.79M |
| QoQ Change | — | — | -77.3% | -74.7% | +392.0% | -30.9% | +32.9% | -92.0% | +257.8% | +739.8% | -79.4% | +116.5% | +48.2% | +700.7% | -11.4% | -4.8% | -2.5% |
| YoY Change | — | — | — | — | — | -80.5% | +14.1% | -64.0% | -73.8% | +218.1% | -50.6% | >999% | +455.9% | +430.0% | >999% | +900.4% | +558.0% |
Range$0.00 – $143.33M
Avg YoY Growth+477.1%
Median YoY Growth+324.1%
Current Streak3 quarters decline
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's other non-current liabilities?
- Royalty Pharma (RPRX) reported other non-current liabilities of $117.79M in Q1 2026.
- How has Royalty Pharma's other non-current liabilities changed year-over-year?
- Royalty Pharma's other non-current liabilities increased by 558.0% year-over-year, from $17.90M to $117.79M.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.